Navigation Links
Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex
Date:3/10/2008

dministered under the supervision of a qualified physician who is experienced in allogeneic hematopoietic stem cell transplantation, the use of cancer chemotherapeutic drugs, and the management of patients with severe pancytopenia. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available. SEE "WARNINGS" SECTION OF FULL PRESCRIBING INFORMATION FOR INFORMATION REGARDING BUSULFAN-INDUCED PANCYTOPENIA IN HUMANS.

At the recommended dosage, IV Busulfex produced profound myelosuppression in all patients (i.e., severe granulocytopenia, thrombocytopenia, anemia, or a combination thereof). Frequent complete blood counts should be monitored during treatment and until recovery. Hepatic veno-occlusive disease was diagnosed in 5/61 patients and was fatal in 2/5 cases. Anticonvulsant prophylactic therapy should be administered prior to treatment. Caution should be exercised in patients with a history of seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs. Bronchopulmonary dysplasia with pulmonary fibrosis is a rare but serious condition following chronic busulfan therapy. Women of childbearing potential should be advised to avoid becoming pregnant as busulfan may cause fetal harm.

The most common nonhematological adverse events were nausea (92% mild/moderate, 7% severe), stomatitis (71% grade 1-2, 26% grade 3-4), vomiting (95% mild/moderate), anorexia (64% mild/moderate, 21% severe), diarrhea (75% mild/moderate, 5% grade 3-4), insomnia (83% mild/moderate, 1% severe), and fever (78% mild/moderate, 3% life-threatening).(1)

Please see FULL PRESCRIBING INFORMATION, including Boxed WARNING for Busulfex (http://www.ivbusulfex.com/29932_PI.pdf).(1)

About Otsuka Pharmaceutical Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a healthcare company with the
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd., and PDL BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... launch product immediately, NATICK, Mass., April 17 ... announced that it has received approval for,the sale ... Canada. The Company reported that Health Canada,s Therapeutic,Products ... medical devices, has approved its use. The Company ...
... Syngenta today,announced that it will build a new biotech ... be on early-stage evaluation of GM and,native traits for ... areas of yield,improvement, drought resistance, disease control and biomass ... scope and will complement,Syngenta,s biotech research activities in the ...
... NexGenix Pharmaceuticals, presented,data on its Hsp90 inhibitor ... AACR,in San Diego today. The company presented data ... several novel, radicicol-based,Hsp90 inhibitors in its compound series., ... xenograft models,without evidence for liver and kidney toxicity. ...
Cached Biology Technology:Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System 2Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System 3Syngenta To Build Major Global Biotech Research Center in Beijing, China 2Syngenta To Build Major Global Biotech Research Center in Beijing, China 3NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2
... patients, own immune cells to target tumors have yielded promising ... also receive large doses of drugs designed to help immune ... Now a team of MIT engineers has devised a ... the backs of the cells sent in to fight the ...
... expensive DNA sequencing strategy, scientists have discovered genetic alterations ... rare disorder that causes multiple birth defects and mental ... new approach sequences just the exome, the 1-2 percent ... Kabuki syndrome, which has an estimated incidence of ...
... Stanley, Inc. (NYSE: www.stanleyassociates.com for ... this press release about our expectations about future ... the words "estimates," "anticipates," "plans," "expects" and similar ... the Private Securities Litigation Reform Act of 1995. ...
Cached Biology News:Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells 2Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells 3Discovered gene causes Kabuki syndrome 2Discovered gene causes Kabuki syndrome 3
... FLISP Assay with FAM-Labeled Substrate (green ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...
Request Info...
... Array (MSTA) slides were designed to study protein ... multiple species. Tissue slices from three different ... can then be treated as a single histological ... situ hybridization. This format allows a ...
... Pulser Xcell eukaryotic system, 100 ... is used for electroporation of ... the main unit, CE module ... or square-wave pulses, ShockPod shocking ...
Biology Products: